Pfizer has received FDA approval for Hympavzi, a new treatment for hemophilia A and B in patients aged 12 and older without inhibitor antibodies. Hympavzi, administered via a pre-filled auto-injector pen, offers a more convenient alternative to intravenous infusions. This approval follows Pfizer’s recent success with its hemophilia B gene therapy Beqvez.
Hympavzi’s phase 3 trial results showed significant reductions in bleeding episodes, with a 92% decrease among patients switching from intravenous therapies. With a wholesale acquisition cost of $795,600, the drug is priced competitively within the hemophilia market. Pfizer expects to launch the product this quarter, offering patients a more manageable treatment option.
Pfizer’s new treatment aims to address the burden of frequent intravenous infusions faced by many hemophilia patients. As part of Pfizer’s broader hemophilia portfolio, including the gene therapy giroctocogene fitelparovec, the approval of Hympavzi marks another step in advancing hemophilia care. Hemophilia impacts over 800,000 people worldwide, and Pfizer’s innovations provide new, potentially life-changing options.
Click here to read the original news story.